EMD-640744 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This EMD-640744 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether EMD-640744 can convert its Therapeutic vaccine profile and survivin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | EMD-640744 (query alias: EMD-640744) |
|---|---|
| Modality / target | Therapeutic vaccine; survivin; survivin modulators, Immunostimulants, T lymphocytes stimulants |
| Highest global status | Phase 2 |
| Originator | Merck Serono SA |
| Active developers | IMV, Inc., Merck Serono SA, Immunovaccine Technologies, Inc. |
The MCP disease footprint includes Diffuse large B-cell lymphoma recurrent, Diffuse large B-cell lymphoma refractory, Diffuse Large B-Cell Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04920617 | Phase 2 | Recruiting | 102 | Objective response rate (ORR) in each of the study arms |
| NCT03349450 | Phase 2 | Completed | 25 | Objective Response Rate Using Modified Cheson Criteria to Treatment With DPX-Survivac and Low Dose Cyclophosphamide Administered Together With Pembrolizumab in Participants With Recurrent, Survivin-expressing B Cell Lymphomas |
| NCT05243524 | Phase 2 | Terminated | 16 | Objective Response Rate (ORR) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Phase 1/2; n=47; evaluation: Positive. Reported fields: ORR = 40.0 % ; ORR = 24.0 % ; ORR = 16.0 %
Maveropepimut-S, an immune-educating therapy with durable clinical benefit in patients with recurrent ovarian cancer (180)
Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Adverse Event: injection site reactions = The most common adverse events were grade 1 and 2 injection site reactions
Abstract CT035: Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer
Not Applicable; n=17; evaluation: Positive. Reported fields: AE = The combination was well-tolerated, with majority of AEs being grade 1 or grade 2.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
EMD-640744 addresses Diffuse large B-cell lymphoma recurrent, Diffuse large B-cell lymphoma refractory, Diffuse Large B-Cell Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Therapeutic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-02-12 | BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC. | Phase 2 | US$0.8M upfront |
| 2021-12-21 | IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts | Phase 2 | Financial terms not disclosed |
| 2018-09-11 | IMV and Merck join forces to assess the potential of DPX-Survivac in combination with Keytruda for the treatment of five different solid tumor indications. | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Survivin and MAGE-a9 dual-targeted immunotherapy”. The milestone feed surfaced a patent-application signal described as “Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors”. The milestone feed surfaced a patent-application signal described as “Method for improving efficacy of survivin vaccine in treatment of cancer”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
